TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36265101
Drug: TMC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC with intravenous nivolumab (TMC-I): TMC plus nivolumab 20 mg flat dose once every 3 weeks
Study: 34928182
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion (ILE) - 100 ml of 20% ILE bolus followed by 100 ml of 20% ILE infusion over 6 hours
Study: 32275359
Drug: Fire needling
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needling treatment (at Lianquan (CV 23), Fengchi (GB 20), Wangu (GB 12), Shuigou (GV 26), Neiguan (PC 6), and Zusanli (ST 36) without needle retaining every other day)
Study: 32016519
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with simethicone plus NAC 600 mg
Study: 34040762
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin tablets
Study: 34040762
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin tablets
Study: 35505174
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg intravenous rhPro‐UK (n = 40)
Study: 35505174
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous rhPro‐UK (n = 39)
Study: 35505174
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg recombinant tissue plasminogen activator (r‐tPA; n = 40)
Study: 36334720
Drug: Epinephrine 1
Normalized name: epinephrine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 1 mg intranasal spray (neffy)
Study: 36334720
Drug: Manual intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual intramuscular epinephrine 0.3 mg injection
Study: 36334720
Drug: Epinephrine 0.3
Normalized name: epinephrine 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.3 mg autoinjectors (Symjepi)
Study: 36334720
Drug: Epinephrine 0.3
Normalized name: epinephrine 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.3 mg autoinjectors (EpiPen)
Study: 32147750
Drug: SPT-07A 10
Normalized name: NV-07a
DrugBank: NV-07a (DB05845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPT-07A 10 mg
Study: 32147750
Drug: SPT-07A 20
Normalized name: NV-07a
DrugBank: NV-07a (DB05845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPT-07A 20 mg
Study: 32147750
Drug: SPT-07A 40
Normalized name: NV-07a
DrugBank: NV-07a (DB05845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPT-07A 40 mg
Study: 33307959
Drug: Dopamine antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine antagonist
Study: 33165964
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist
Study: 35239511
Drug: Gut decontamination
Normalized name: BACILLUS CLAUSII 2000000000 ORAL SUSPENSION [SANA GUT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut decontamination (GD) with oral vancomycin-polymyxin B from day -5 through neutrophil engraftment
Study: 32978183
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving care accompanied by reinstruction and remotivation by dental assistants using the 'Oral Health Toolbox'.
Study: 33558263
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin plus epinephrine (EI)
Study: 33558263
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin plus sterile water (WI)
Study: 34547165
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping with manual therapy (KTMT)
Study: 36176051
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 30–720 mg vutiglabridin
Study: 36176051
Drug: 240–480 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240–480 mg vutiglabridin once daily for 14 days
Study: 36176051
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg single dose of vutiglabridin with a high-fat meal
Study: 32678452
Drug: Inhaled vaporized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vaporized cannabis (4.4% Δ‐9‐tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily for 5 days
Study: 32678452
Drug: Inhaled vaporized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vaporized placebo cannabis 3 times daily for 5 days
Study: 32678452
Drug: Inhaled vaporized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vaporized cannabis
Study: 32678452
Drug: Inhaled vaporized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vaporized placebo cannabis
Study: 35678800
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg/day orally for 12 weeks)
Study: 35678800
Drug: Telmisartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20 mg/day orally for 8 weeks)
Study: 35678800
Drug: Placebo (carboxy-methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (carboxy-methyl cellulose once daily)
Study: 32111313
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (1 mL/L Enrofloxacin 10% in drinking water for 10 days)
Study: 32111313
Drug: Capsulated immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsulated immune yolk (12.8 g/kg)
Study: 34658020
Drug: Intraperitoneal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal ropivacaine (150 mg in 20 mL saline)
Study: 35301810
Drug: Rilzabrutinib 100
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib 100 mg + Ritonavir 100 mg
Study: 35301810
Drug: Rilzabrutinib 1200
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib 1200 mg
Study: 35301810
Drug: Rilzabrutinib 400
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib 400 mg + Ritonavir 100 mg
Study: 34626108
Drug: Smoking Cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking Cessation Medication (SCM)
Study: 36164138
Drug: IV Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Isatuximab (10 mg/kg)
Study: 36164138
Drug: SC Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC Isatuximab (1000 mg)
Study: 36164138
Drug: SC Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC Isatuximab (1400 mg)
Study: 36164138
Drug: OBDS Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OBDS Isatuximab (1400 mg)
Study: 36164138
Drug: SC Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC Isatuximab (1400 mg) + OBDS
Study: 32540634
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of standardized ashwagandha extract (Shoden®) once daily for six weeks
Study: 34217572
Drug: Standard dose-interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose-interval (2 weeks)
Study: 34217572
Drug: Extended dose-interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dose-interval (6 months)
Study: 34217572
Drug: Both dose-intervals
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dose-intervals
Study: 36198461
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TT) + Long pulse width stimulation (LPWS)
Study: 36198461
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TT) + neuromuscular electrical stimulation via telehealth
Study: 35217515
Drug: PRN ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PRN ranibizumab monotherapy, n=119
Study: 33449396
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (0.2 mL)
Study: 33449396
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (58.5 mg/mL; active control)
Study: 33449396
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9 mg/mL; passive control)
Study: 32080074
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus (PL) 1,000 mg
Study: 32080074
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus (PL) 1,500 mg
Study: 35809255
Drug: O‐R electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐R electric rechargeable toothbrush (Oral‐B iO with Oral‐B Gentle Care brush head)
Study: 35809255
Drug: Soft manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft manual toothbrush (Oral‐B Indicator)
Study: 35022317
Drug: High-caloric fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-caloric fatty supplement (HCFS; 405 kcal/day, 100% fat)
Study: 35022317
Drug: Ultra-high-caloric fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high-caloric fatty supplement (UHCFS; 810 kcal/day, 100% fat)
Study: 35022317
Drug: Ultra-high-caloric, carbohydrate-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high-caloric, carbohydrate-rich supplement (UHCCS; 900 kcal/day, 49% carbohydrates)
Study: 35022317
Drug: Open control
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open control (OC) group without any supplement
Study: 33199226
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine perfusion
Study: 33048923
Drug: SMASH intervention
Normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMASH intervention (pharmacist-led Safety Medication dASHboard)
Study: 35412099
Drug: Heparin-free protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-free protocol
Study: 32507535
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 6 drops of 40% damask rose essential oil
Study: 34410498
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide (White Class 10%, FGM) applied once daily for 60 min to the buccal surface for 14 days
Study: 34410498
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide (White Class 10%, FGM) applied once daily for 60 min to the lingual surface for 14 days
Study: 33084088
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor blockade (using exendin9-39) before surgery
Study: 33084088
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor blockade after RYGB
Study: 32091596
Drug: 3-dose bivalent
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose bivalent HPV vaccine
Study: 32091596
Drug: 1-dose bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose bivalent HPV vaccine
Study: 32192811
Drug: RTS,S/AS01 co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 co-administered with YF and MR vaccines
Study: 32192811
Drug: YF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF and MR vaccines alone
Study: 36431088
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (sodium picosulfate plus laxatives, enemas, increased fiber, and fluid intake)
Study: 33046141
Drug: Glyceride formulation
Normalized name: coco-glycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceride formulation of EPA + DHA (2.8 g)
Study: 33046141
Drug: Ethyl ester
Normalized name: Amben ethyl ester
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl ester formulation of EPA + DHA (2.8 g)
Study: 33359437
Drug: Duodenal mucosal
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal mucosal resurfacing (DMR) combined with glucagon-like peptide-1 receptor agonist (GLP-1RA) (liraglutide) and lifestyle counseling
Study: 36192223
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application (app) for oral hygiene guidance and motivation
Study: 36192223
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene (SOH) instructions
Study: 33909330
Drug: Spironolactone (SPL)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (SPL) 200 mg/day
Study: 33445588
Drug: Somatosensory rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatosensory rehabilitation in addition to standard physical therapy for 8 weeks
Study: 33445588
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy for 8 weeks
Study: 32193981
Drug: LIVE‐LiFE intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIVE‐LiFE intervention (strength and balance training integrated into daily habits, 8 visits over 12 weeks, plus US$500 in home safety changes, vision contrast screening, and medication recommendations)
Study: 34673998
Drug: Hyperosmolar dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar dextrose injection (12.5%)
Study: 34257675
Drug: ω‐3FA concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3FA concentrate 2000 mg (Group A)
Study: 34257675
Drug: ω‐3FA concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3FA concentrate 2000 mg + PCC200 mcg (Group B)
Study: 34257675
Drug: ω‐3FA concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3FA concentrate 2000 mg + PCC400 mcg (Group C)
Study: 33824980
Drug: Cogmed Working
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cogmed Working Memory Training at home on a tablet device (N=24)
Study: 35164864
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment for one week
Study: 34623318
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text assessment (n=50)
Study: 33098496
Drug: Indoor and
Normalized name: Indoor and Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor and outdoor dose rates (Ḋ), age‐dependent annual effective doses (AED), organ‐specific doses, lifetime attributable cancer risk
Study: 33094958
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy (triple therapy with esomeprazole, amoxicillin, and clarithromycin for 10 days)
Study: 33094958
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy (triple or quadruple therapy with esomeprazole, metronidazole, tetracycline, and bismuth for 10 days based on genotype markers of resistance)
Study: 34762351
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg daily intravenously
Study: 34762351
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard COVID-19 pharmacotherapy)
Study: 35987977
Drug: Intravenous lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lorazepam
Study: 34032829
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 20% hypertonic saline solution plus standard care
Study: 35762095
Drug: OHI (electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI (electric toothbrush and intensive oral hygiene manoeuvre adaptation)
Study: 32207659
Drug: Optimal pharmacologic
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacologic therapy (OPT)
Study: 32207659
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy pacemakers (CRT-P)
Study: 36456409
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication reconciliation (MC)
Study: 33143640
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 ml/day)
Study: 38018702
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no treatment
Study: 34593990
Drug: AdVEGF-D gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdVEGF-D gene therapy (GT)
Study: 35938348
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for insomnia (CBT‐I)
Study: 36163030
Drug: Culturally tailored
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally tailored cognitive-behavioural intervention (5 sessions, 30-35 min each, weekly)
Study: 33812334
Drug: Nab-paclitaxel/Gemcitabine (NAB-P/G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel/Gemcitabine (NAB-P/G)
Study: 32843098
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone (16 mg/24 hours for 5 days followed by 8 mg/24 hours for 5 days) + standard ICU care
Study: 32843098
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone + standard ICU care
Study: 32583948
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with lenalidomide and dexamethasone (POLLUX)
Study: 32583948
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with bortezomib and dexamethasone (CASTOR)
Study: 33581737
Drug: Canagliflozin (CG)
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin (CG) 100 mg
Study: 33983794
Drug: Sacubitril/valsartan 97/103mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 97/103mg twice daily
Study: 33983794
Drug: Valsartan 160mg
Normalized name: VALSARTAN 160MG CAP
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160mg twice daily
Study: 33415867
Drug: Acupoint thread-embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread-embedding therapy
Study: 32207705
Drug: Complex biologically
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex biologically active food supplement Osteomed forte prescribed for 12 months (SG1 and SG2)
Study: 32207705
Drug: Complex biologically
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex biologically active food supplement Osteomed forte prescribed for 12 months (SG1)
Study: 34863038
Drug: LY2409021 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2409021 (100 mg)
Study: 32135429
Drug: Buprenorphine and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine and naloxone treatment
Study: 32881071
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) + Treatment as Usual (TAU) (n = 23)
Study: 32881071
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) (n = 24)
Study: 32615488
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g lyophilized juçara for 6 weeks
Study: 33845035
Drug: 21 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 Gy intraoperative radiotherapy with electrons (ELIOT) in a single dose to the tumour bed during surgery
Study: 36308305
Drug: Tablet app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet app-based program (n=26)
Study: 32615994
Drug: Inhaled granulocyte-macrophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) for 6 months
Study: 32959232
Drug: Younger male
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger male patients with pancreatic body and tail cancer, AJCC 8th N1 stage, without microvascular and peripancreatic fat invasion, CA 19-9 > 200 U/ml.
Study: 32946355
Drug: Consolidation radiotherapy
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation radiotherapy (cRT) with a median dose of 30.6 Gy (range, 24-36 Gy)
Study: 34743579
Drug: Erenumab (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (70 or 140 mg/month)
Study: 34743579
Drug: Topiramate (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (50-100 mg/day)
Study: 33951374
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine (5 µg of recombinant spike protein with 50 µg of Matrix-M1 adjuvant)
Study: 37214968
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine
Study: 33443609
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TT)
Study: 33443609
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TT) combined with resistance training (TT + RT)